

Anti-GD2 Antibody (Naxitamab)

Introduction

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 (hu3F8). Naxitamab is used in the study of neuroblastoma, osteosarcoma, and other GD2-positive cancers.

Product parameters

Alternative Names	Naxitamab-gqgk, DANYELZA, Hu3F8
Target Accession	-
Target	GD2
CAS number	1879925-92-4
Molecular Weight	144.38 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

